Business Description
Merrimack Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US5903282094
Description
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.91 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26 | |||||
| 3-Year EPS without NRI Growth Rate | 36.7 | |||||
| 3-Year FCF Growth Rate | 32.6 | |||||
| 3-Year Book Growth Rate | 3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.61 | |||||
| 9-Day RSI | 82.79 | |||||
| 14-Day RSI | 78.96 | |||||
| 6-1 Month Momentum % | 14.99 | |||||
| 12-1 Month Momentum % | 18.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.78 | |||||
| Quick Ratio | 10.78 | |||||
| Cash Ratio | 10.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 337.01 | |||||
| ROA % | 311.38 | |||||
| ROIC % | -1082.93 | |||||
| ROC (Joel Greenblatt) % | -3585.71 | |||||
| ROCE % | -3.8 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1.09 | |||||
| Shiller PE Ratio | 11.72 | |||||
| PB Ratio | 0.99 | |||||
| Price-to-Tangible-Book | 0.99 | |||||
| EV-to-EBIT | 9.01 | |||||
| EV-to-EBITDA | 9.01 | |||||
| EV-to-FCF | 8.21 | |||||
| Price-to-Net-Current-Asset-Value | 0.99 | |||||
| Price-to-Net-Cash | 0.99 | |||||
| Earnings Yield (Greenblatt) % | 11.1 | |||||
| FCF Yield % | -1.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MACK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merrimack Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 13.87 | ||
| Beta | 0 | ||
| Volatility % | 11.94 | ||
| 14-Day RSI | 78.96 | ||
| 14-Day ATR ($) | 0.045329 | ||
| 20-Day SMA ($) | 15.0305 | ||
| 12-1 Month Momentum % | 18.5 | ||
| 52-Week Range ($) | 11.53 - 15.89 | ||
| Shares Outstanding (Mil) | 14.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merrimack Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merrimack Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Merrimack Pharmaceuticals Inc Frequently Asked Questions
What is Merrimack Pharmaceuticals Inc(MACK)'s stock price today?
The current price of MACK is $15.13. The 52 week high of MACK is $15.89 and 52 week low is $11.53.
When is next earnings date of Merrimack Pharmaceuticals Inc(MACK)?
The next earnings date of Merrimack Pharmaceuticals Inc(MACK) is 2025-03-07 Est..
Does Merrimack Pharmaceuticals Inc(MACK) pay dividends? If so, how much?
Merrimack Pharmaceuticals Inc(MACK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers